1. Patient should not be on any medications that may influence Insulin levels, if possible, for at least 48 hours prior to collection.
2. Patient should be fasting 10 hours prior to collection. Patient may drink plain water, no other liquid is acceptable.
Specimen Type: Plasma
Container/Tube: Z tube (MCL T701)
Specimen Volume: 3 mL
Collection Instructions: Draw 10 mL of blood in special Z-tube, pre-chilled (MCL T701). Separate plasma from cells immediately after draw and freeze immediately after separation. Send 3 mL of plasma frozen in a plastic vial.
|Hemolysis||Mild reject; Gross reject|
|Lipemia||Mild reject; Gross reject|
|Other||Specimens other than collected in Z tube (MCL T701).|
|Specimen Type||Temperature||Time||Special Container|
|Plasma||Frozen (preferred)||60 days|
Pancreastatin is a 49 amino acid peptide produced by degradation of Chromo-granin A. It inhibits Chromogranin A and Parathyroid Hormone release. Pancreastatin also inhibits release of Somatostatin upon glucose stimulation. It may also control carbohydrate metabolism and hyperglycemia. Although there are no compounds with significant structural homology with Pancreastatin, there are minor similarities to Gastrin and Anti-Diuretic Hormone. Pancreastatin reduces the early phase of Glucose induced Insulin release. Suppression of Insulin release upon Glucose stimulation is a characteristic feature of Type II Diabetes. Pancreastatin could play an important therapeutic role in the treatment of diabetes. Pancreastatin also inhibits release of Somatostatin. It may also control carbohydrate metabolism and hyperglycemia.
1. Raines D, Chester M, Diebold AE, et al. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans. Pancreas. 2012;41(4):508-511.
2. O’Dorisio TM, Krutzik SR, Woltering EA, et al. Development of a highly sensitive and specific carboxy-terminal human Pancreastatin assay to monitor neuroendocrine tumor behavior. Pancreas. 201;39(5):611-616.
3. Pier E, Mirelles P, Silvestre RA, et al. Pancreastatin inhibits insulin secretion as induced by glucagon, vasoactive intestinal polypeptide, gastric inhibiting peptide, and 8-cholecystokinin in the perfused rat pancreas. Metabolism. 1989;38:679-82.
4. Tatemoto K, Efendi S, Mutt S, et al. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature. 1986;324:476-8.
5. Calhoun K, Toth-Fejel S, Chee J, et al. Serum peptide profiles in patients with carcinoid tumors. Am J Surg. 2003;186(1):28-31.
6. Syverson U, Jacobsen MN, O’Connor DT, et al. Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia. Neuropeptides. 1994;26(3):201-6.
7. Kogner P, Bjellerup P, Svensson T, et al. Pancreastatin immunoreactivity in favourable childhood neuroblastoma and ganglioneuroma. Eur J Cancer 1995;31A(4):557-60.
8. Desai DC, O’Dorisio TM, Schirmer WJ, et al. Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analog therapy in metastatic neuroendocrine tumors. Regul Pept. 2001;96(3):113-17.
Monday through Friday
This radioimmunoassay was developed and its performance characteristics determined by Inter Science Institute. It has not been cleared or approved by the FDA and such approval or clearance is not required at this time. Values obtained with differnt methods, different laboratories or with kits cannot be used interchangeably with the results on this report. The results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.
|Test Id||Test Order Name||Order LOINC Value|
|Result Id||Test Result Name||
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.